You are here

Lenvima

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

CP Wire

Flag link:

Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma

hepatocellular carcinoma

Flag link:

European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade

European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade

CP WIre

hepatocellular carcinoma

Flag link:

European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade

hepatocellular carcinoma

Flag link:

Eisai-Merck partnership picks up first-line Lenvima approval

Eisai-Merck partnership picks up first-line Lenvima approval

Biopharma Dive

hepatocellular carcinoma

Flag link:

Japan's Eisai sets price tag of about $16,000 on liver cancer drug

Japan's Eisai sets price tag of about $16,000 on liver cancer drug

Yahoo/Reuters

Flag link:

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action

Eisai's Lenvima posts big growth numbers as Merck collaboration rolls into action

Fierce Pharma

Flag link:

FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach

FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach

Fierce Pharma

Flag link:

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star

Endpoints

Flag link:

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector

GoinPharma

Bristol-Myers Squibb

Flag link:

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Merck, Eisai nab Keytruda-Lenvima 'breakthrough' in quickly crowding kidney cancer field

Fierce Pharma

Flag link:

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Fierce Pharma

Flag link:

Eisai's kidney drug wins expanded indication in the U.S.

Eisai's kidney drug wins expanded indication in the U.S.

BioPharma Dive

advanced renal cell carcinoma

Flag link:

Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Eisai scores FDA priority review for bigger Lenvima use in kidney cancer

Fierce Pharma

priority review

Flag link:

Eisai's launch for 'crown jewel' Lenvima tracking better than execs expected

Eisai's launch for 'crown jewel' Lenvima tracking better than execs expected

Fierce Pharma Marketing

Flag link:

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Eisai Says New Cancer Drug Reaching Patients Faster Than Planned

Bloomberg

Flag link:

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Eisai gets EMA nod for Lenvima just weeks after FDA approval

Fierce Pharma

Flag link:

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Fierce Pharma Marketing

Flag link:

FDA approves Eisai's thyroid cancer drug

FDA approves Eisai's thyroid cancer drug

Yahoo/Reuters

Flag link: